Browse ETV7

Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00178 Ets-domain
PF02198 Sterile alpha motif (SAM)/Pointed domain
Function

Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Isoform A does not seem to have a repressor activity. Isoform C does not seem to have a repressor activity.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04320 Dorso-ventral axis formation
Reactome -
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ETV7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ETV7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ETV7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1230.813
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.140.897
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1010.897
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7210.139
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0130.481
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3590.852
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.3310.0297
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.920.0379
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.650.525
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3330.255
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9490.582
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4520.00142
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ETV7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ETV7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ETV7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ETV7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ETV7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ETV7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ETV7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolETV7
Nameets variant 7
Aliases TEL-2; TEL2 oncogene; ets variant gene 7 (TEL2 oncogene); TELB; ETS translocation variant 7; ETS-related pro ......
Chromosomal Location6p21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ETV7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.